August 28, 2025 a 01:00 pm
MRK: Fundamental Ratio Analysis - Merck & Co., Inc.
Merck & Co., Inc. has shown stable performance in the healthcare sector with a diversified portfolio in pharmaceuticals and animal health. However, fundamental scores suggest areas for improvement, particularly in returns on equity and assets. Collaboration efforts in the HIV treatment landscape could provide significant future potential.
Fundamental Rating
The current fundamental ratings for Merck & Co., Inc. suggest a moderate performance with a need for improvement in areas like return ratios.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
A comparison with past data shows consistency in certain metrics, but overall scores have improved.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-27 | 2 | 5 | 1 | 1 | 1 | 2 | 1 |
| Previous | 0 | 5 | 1 | 1 | 1 | 2 | 1 |
Analyst Price Targets
Analysts present optimistic price targets, with a consensus leaning towards moderate upward movement.
| High | Low | Median | Consensus |
|---|---|---|---|
| $98 | $82 | $90 | $90 |
Analyst Sentiment
Analyst sentiment shows a positive outlook with a predominant buy recommendation.
| Recommendation | Number | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 25 | |
| Hold | 9 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Merck & Co., Inc. presents an interesting investment case with stable fundamentals in key areas but shows room for improvement in terms of returns. The positive analyst sentiment and strategic collaborations could be key drivers for growth, though potential investors should monitor the company's efforts to enhance its ROE and ROA. Overall, while rated as a buy, careful attention to financial health and strategic progress is advisable.